News
Why Nektar Therapeutics Shares Are Soaring 13% Higher
After the company reported third-quarter earnings that were better than industry watchers' forecasts, shares in Nektar Therapeutics (NASDAQ: NKTR) are popping 13.1% higher today as of 2:45 p.m.....
New Contracts and Products Help Emergent BioSolutions Inc Get It Done
Emergent BioSolutions (NYSE: EBS) continues toward its goal of having $1 billion in revenue in 2020 with a solid third-quarter performance that exceeded its own guidance of revenue in the range of....
Why Halozyme Therapeutics, Inc. Deserves Its 52-Week High
In response to the company posting pleasing third-quarter results and boosting guidance, shares of Halozyme Therapeutics (NASDAQ: HALO), a biotech that focuses on making other drugs more....
How to Invest in Biotech Stocks
$33,800.That's how much you'd have if you'd invested $10,000 in Alnylam stock just one year ago.Sound enticing? How about $154,980?Continue readingSource: Fool.com
Here's Why Editas Medicine Collapsed at Market Open Today
Shares of CRISPR gene-editing pioneer Editas Medicine (NASDAQ: EDIT) fell 12.1% shortly after the market opened Wednesday morning. Why? Although the company reported third-quarter 2017 earnings....
Why Spectrum Pharmaceuticals Stock Soared in October
Spectrum Pharmaceuticals (NASDAQ: SPPI), a small-cap oncology company, saw its shares gain a whopping 39.2% in October, according to S&P Global Market Intelligence. The drugmaker's stock took....
Here's Why Merck & Co., Inc. Tanked 14% in October
Shares of America's second largest pharmaceutical company, Merck & Co., Inc. (NYSE: MRK) suffered their worst month in years, falling 14% in October, according to data from S&P Global....
Here's What Cost GlaxoSmithKline PLC Nearly $10 Billion in Market Cap in October
Shares of U.K.-based Big Pharma giant GlaxoSmithKline (NYSE: GSK) tumbled during the month of October, according to data from S&P Global Market Intelligence, losing nearly $10 billion in....
Is the Worst Behind Valeant Pharmaceuticals' Stock?
Valeant Pharmaceuticals' (NYSE: VRX) is knee-deep in a transformation that it hopes will allow it to regain its top-tier status with investors. The company's selling assets and funneling cash flow....
Despite FDA OK, Keryx Sinks on Gross-to-Net Surprise
Keryx Pharmaceuticals' (NASDAQ: KERX) Auryxia just won the Food and Drug Administration (FDA) green light for boosting iron levels in non-dialysis chronic kidney disease patients, but shares....
Why Neos Therapeutics Inc Rose 13.7% In October
Shares of Neos Therapeutics (NASDAQ: NEOS), a small-cap pharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), jumped 13.7% in October according to data from S&P....
Why Inovio Pharmaceuticals Stock Sank in October
According to S&P Global Market Intelligence, shares of the DNA vaccine maker Inovio Pharmaceuticals (NASDAQ: INO) shed 8% of their value last month. On the bright side, this high single-digit....
Here's Why Emergent Biosolutions Dropped as Much as 11.8% Today
Shares of public health threat neutralizer Emergent Biosolutions (NYSE: EBS) fell nearly 12% today for, well, no compelling reason at this time. Sometimes stocks go up, and sometimes they go down.....
Here's Why Invitae Rose as Much as 13.8% Today
Shares of genomics leader Invitae (NYSE: NVTA) rose nearly 14% Tuesday after the company reported third-quarter 2017 earnings Monday afternoon. Investors have become accustomed to eye-popping....
Novo Nordisk A/S Slogs Through the Year
Novo Nordisk (NYSE: NVO) continues to slog through the year, dealing with losing exclusivity on hormone-replacement therapy Vagifem and pricing pressure. The year-over-year comparison for Vagifem....
Why Supernus Pharmaceuticals Inc. Is Having a Rather Non-Super Day
Shares of Supernus Pharmaceuticals (NASDAQ: SUPN), a developer of drugs that target diseases of the central nervous system, plunged as much as 19% during Tuesday's trading session following the....
Here's Why Spark Therapeutics, Inc. Fell 9.3% in October
Shares of Spark Therapeutics, Inc. (NASDAQ: ONCE), a clinical-stage biotech advancing a once-and-done gene therapy approach to treating genetic disorders, have given back some of August's gains.....
The Single Event That Rocketed Arena Pharmaceuticals, Inc. Higher by 10% in October
Shares of Arena Pharmaceuticals (NASDAQ: ARNA), a small-cap biotech company with a focus on a broad array of specialty disease indications, vaulted higher by 10% during the month of October,....
The Big Reason ImmunoGen, Inc. Shed 24% of Its Value in October
Shares of ImmunoGen (NASDAQ: IMGN), a small-cap biotech company focused on the development of antibody-drug conjugates for the treatment of cancer, plunged 24% in October, according to data from....
Here's Why Teligent Stock Was Cut Nearly in Half Today
Shares of specialty generic pharmaceutical manufacturer Teligent (NASDAQ: TLGT) dropped as much as 46% today after investors digested the company's third-quarter 2017 results. Operations appeared....
Here's Why Advanced Accelerator Application SA Rose 20% in October
Shares of Advanced Accelerator Application SA (NASDAQ: AAAP), a manufacturer of tracers used for medical imaging, rose 19.8% in October according to data from S&P Global Market Intelligence. A....
Why Celldex Therapeutics Jumped Higher Today
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is up 16% at 12:04 p.m. EST after releasing third-quarter earnings this morning, although the stock move likely has more to do with data released in....
Why Valeant Pharmaceuticals International Stock Is Shooting Higher Today
Valeant Pharmaceuticals International (NYSE: VRX) stock is up by double-digits today on heavy volume as the result of a better-than-expected third-quarter earnings release. Although the company....
Celldex Therapeutics, Inc.'s Most Important Takeaway From Q3 Isn't a Number
Investors view quarterly updates from clinical-stage biotechs in a very different way than they do for other companies. The bottom line isn't nearly as important for these small biotechs as are....
The Clear-Cut Reason Alexion Pharmaceuticals Tanked 15% in October
Shares of Alexion Pharmaceuticals (NASDAQ: ALXN), a large-cap biotech company with a focus on rare genetic diseases, tumbled 15% during the month of October, according to data from S&P Global....